tert-Butyl ((3S,4R)-3-hydroxytetrahydro-2H-pyran-4-yl)carbamate

Catalog No. :
ACLCKV759
CAS No. :
2408937-23-3
Molecular Formula :
C10H19NO4
Molecular Weight :
217.26

IUPAC Name:tert-butyl ((3S,4R)-3-hydroxytetrahydro-2H-pyran-4-yl)carbamate

tert-Butyl ((3S,4R)-3-hydroxytetrahydro-2H-pyran-4-yl)carbamate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100mg97%$219.00Login to see priceIn stockInquiry
250mg97%$313.00Login to see priceIn stockInquiry
500mg97%$563.00Login to see priceIn stockInquiry
1g97%$938.00Login to see priceIn stockInquiry
5g97%$2812.00Login to see priceIn stockInquiry
10g97%$4686.00Login to see priceIn stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Nametert-Butyl ((3S,4R)-3-hydroxytetrahydro-2H-pyran-4-yl)carbamate
IUPAC Nametert-butyl ((3S,4R)-3-hydroxytetrahydro-2H-pyran-4-yl)carbamate
Molecular FormulaC10H19NO4
Molecular Weight217.26
SMILESO=C(OC(C)(C)C)N[C@H]1[C@H](O)COCC1
InChI KeyKWKVNKDJIRDXRH-HTQZYQBOSA-N
Synonym2408937-23-3 | D79041 | SCHEMBL3886187 | t-Butyl N-[(3S,4R)-3-hydroxytetrahydropyran-4-yl]carbamate | trans-(3-Hydroxy-tetrahydro-pyran-4-yl)-carbamic acid tert-butyl ester | rac-tert-butyl N-[(3R,4S)-3-hydroxyoxan-4-yl]carbamate | (3S,4R)-(3-Hydroxy-tetr
CAS No.2408937-23-3
PubChem CID68826975

Synthetic Route by SureRoute

1. ACLCKV759 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACJDLM038 route compound structure diagram
    ACJDLM0381630815-44-9 In Stock
  4. Then
  5. ACLCKV759 route product structure diagram
    ACLCKV7592408937-23-3 In Stock
Inquiry

2. ACLCKV759 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACLCKV759 route product structure diagram
    ACLCKV7592408937-23-3 In Stock
Inquiry

Comments (0)